BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 29358704)

  • 41. Overexpression of MSK1 is associated with tumor aggressiveness and poor prognosis in colorectal cancer.
    Fu X; Fan X; Hu J; Zou H; Chen Z; Liu Q; Ni B; Tan X; Su Q; Wang J; Wang L; Wang J
    Dig Liver Dis; 2017 Jun; 49(6):683-691. PubMed ID: 28314603
    [TBL] [Abstract][Full Text] [Related]  

  • 42. PPFIA1 is upregulated in liver metastasis of breast cancer and is a potential poor prognostic indicator of metastatic relapse.
    Yang J; Wu NN; Huang DJ; Luo YC; Huang JZ; He HY; Lu HL; Song WL
    Tumour Biol; 2017 Jul; 39(7):1010428317713492. PubMed ID: 28720060
    [TBL] [Abstract][Full Text] [Related]  

  • 43. FOXA1: Growth inhibitor and a favorable prognostic factor in human breast cancer.
    Wolf I; Bose S; Williamson EA; Miller CW; Karlan BY; Koeffler HP
    Int J Cancer; 2007 Mar; 120(5):1013-22. PubMed ID: 17163418
    [TBL] [Abstract][Full Text] [Related]  

  • 44. RSK4 knockdown promotes proliferation, migration and metastasis of human breast adenocarcinoma cells.
    Zhu J; Li QY; Liu JL; Wei W; Yang HW; Tang W
    Oncol Rep; 2015 Dec; 34(6):3156-62. PubMed ID: 26397146
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Expression and mutational analysis of GATA3 in Malaysian breast carcinomas.
    Bong PN; Zakaria Z; Muhammad R; Abdullah N; Ibrahim N; Emran NA; Syed Hussain SN
    Malays J Pathol; 2010 Dec; 32(2):117-22. PubMed ID: 21329183
    [TBL] [Abstract][Full Text] [Related]  

  • 46. ERRα Expression in Bone Metastases Leads to an Exacerbated Antitumor Immune Response.
    Bouchet M; Lainé A; Boyault C; Proponnet-Guerault M; Meugnier E; Bouazza L; Kan CWS; Geraci S; El-Moghrabi S; Hernandez-Vargas H; Benetollo C; Yoshiko Y; Duterque-Coquillaud M; Clézardin P; Marie JC; Bonnelye E
    Cancer Res; 2020 Jul; 80(13):2914-2926. PubMed ID: 32366476
    [TBL] [Abstract][Full Text] [Related]  

  • 47. RSK4 inhibits breast cancer cell proliferation and invasion in vitro, and is correlated with estrogen receptor upregulation in breast cancer.
    Huo H; Ye X; Yang H; Li Q; Jiang Y
    Oncol Rep; 2019 Dec; 42(6):2777-2787. PubMed ID: 31545499
    [TBL] [Abstract][Full Text] [Related]  

  • 48. ERRα promotes breast cancer cell dissemination to bone by increasing RANK expression in primary breast tumors.
    Vargas G; Bouchet M; Bouazza L; Reboul P; Boyault C; Gervais M; Kan C; Benetollo C; Brevet M; Croset M; Mazel M; Cayrefourcq L; Geraci S; Vacher S; Pantano F; Filipits M; Driouch K; Bieche I; Gnant M; Jacot W; Aubin JE; Duterque-Coquillaud M; Alix-Panabières C; Clézardin P; Bonnelye E
    Oncogene; 2019 Feb; 38(7):950-964. PubMed ID: 30478447
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Impact of GATA-3 and FOXA1 expression in patients with hormone receptor-positive/HER2-negative breast cancer.
    Hisamatsu Y; Tokunaga E; Yamashita N; Akiyoshi S; Okada S; Nakashima Y; Taketani K; Aishima S; Oda Y; Morita M; Maehara Y
    Breast Cancer; 2015 Sep; 22(5):520-8. PubMed ID: 24415069
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Down-regulation of TRPS1 stimulates epithelial-mesenchymal transition and metastasis through repression of FOXA1.
    Huang JZ; Chen M; Zeng M; Xu SH; Zou FY; Chen D; Yan GR
    J Pathol; 2016 Jun; 239(2):186-96. PubMed ID: 26969828
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Monitoring metastatic behavior of human tumor cells in mice with species-specific polymerase chain reaction: elevated expression of angiogenesis and bone resorption stimulators by breast cancer in bone metastases.
    van der Pluijm G; Sijmons B; Vloedgraven H; Deckers M; Papapoulos S; Löwik C
    J Bone Miner Res; 2001 Jun; 16(6):1077-91. PubMed ID: 11393785
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Molecular subtype profiling of invasive breast cancers weakly positive for estrogen receptor.
    Sheffield BS; Kos Z; Asleh-Aburaya K; Wang XQ; Leung S; Gao D; Won J; Chow C; Rachamadugu R; Stijleman I; Wolber R; Gilks CB; Myles N; Thomson T; Hayes MM; Bernard PS; Nielsen TO; Chia SK
    Breast Cancer Res Treat; 2016 Feb; 155(3):483-90. PubMed ID: 26846986
    [TBL] [Abstract][Full Text] [Related]  

  • 53. GATA3 cooperates with PARP1 to regulate CCND1 transcription through modulating histone H1 incorporation.
    Shan L; Li X; Liu L; Ding X; Wang Q; Zheng Y; Duan Y; Xuan C; Wang Y; Yang F; Shang Y; Shi L
    Oncogene; 2014 Jun; 33(24):3205-16. PubMed ID: 23851505
    [TBL] [Abstract][Full Text] [Related]  

  • 54.
    Shahi P; Wang CY; Lawson DA; Slorach EM; Lu A; Yu Y; Lai MD; Gonzalez Velozo H; Werb Z
    Proc Natl Acad Sci U S A; 2017 Mar; 114(12):3169-3174. PubMed ID: 28258171
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Mutant GATA3 Actively Promotes the Growth of Normal and Malignant Mammary Cells.
    Emmanuel N; Lofgren KA; Peterson EA; Meier DR; Jung EH; Kenny PA
    Anticancer Res; 2018 Aug; 38(8):4435-4441. PubMed ID: 30061207
    [TBL] [Abstract][Full Text] [Related]  

  • 56. GATA3 somatic mutations are associated with clinicopathological features and expression profile in TCGA breast cancer patients.
    Afzaljavan F; Sadr AS; Savas S; Pasdar A
    Sci Rep; 2021 Jan; 11(1):1679. PubMed ID: 33462316
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Transcription factor-nucleosome dynamics from plasma cfDNA identifies ER-driven states in breast cancer.
    Rao S; Han AL; Zukowski A; Kopin E; Sartorius CA; Kabos P; Ramachandran S
    Sci Adv; 2022 Aug; 8(34):eabm4358. PubMed ID: 36001652
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Dormancy signatures and metastasis in estrogen receptor positive and negative breast cancer.
    Kim RS; Avivar-Valderas A; Estrada Y; Bragado P; Sosa MS; Aguirre-Ghiso JA; Segall JE
    PLoS One; 2012; 7(4):e35569. PubMed ID: 22530051
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Interleukins as Mediators of the Tumor Cell-Bone Cell Crosstalk during the Initiation of Breast Cancer Bone Metastasis.
    Haider MT; Ridlmaier N; Smit DJ; Taipaleenmäki H
    Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33809315
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The ELEANOR noncoding RNA expression contributes to cancer dormancy and predicts late recurrence of estrogen receptor-positive breast cancer.
    Fukuoka M; Ichikawa Y; Osako T; Fujita T; Baba S; Takeuchi K; Tsunoda N; Ebata T; Ueno T; Ohno S; Saitoh N
    Cancer Sci; 2022 Jul; 113(7):2336-2351. PubMed ID: 35415910
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.